![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication December 3, 2004.
Revised February 28, 2005.
Accepted for publication March 1, 2005.
Microdialysis was used to determine the in vivo processes contributing to extracellular glutamate levels in the prefrontal cortex of rats. Reverse dialysis of a variety of compounds proved unable to decrease basal levels of extracellular glutamate, including Na+ and Ca+2 channel blockers, cystine/glutamate exchange (xc-) antagonists, and group I (mGluR1/5) and group II (mGluR2/3) metabotropic glutamate receptor (mGluR) agonists or antagonists. In contrast, extracellular glutamate was elevated by blocking Na+-dependent glutamate uptake (X-AG) with DL-threo-b-benzyloxyaspartate (TBOA) and stimulating group I mGluRs with (RS)-3,5-dihydroxy-phenylglycine (DHPG). The accumulation of extracellular glutamate produced by blocking X-AG was completely reversed by inhibiting system xc- with 4-carboxyphenylglycine (CPG), but not by Na+ and Ca+2 channel blockers. Because CPG also inhibits group I mGluRs, two additional group I antagonists were examined, LY367385 and RS-1-aminoindan-1,5-dicarboxylic acid (AIDA). While LY 367385 also reduced TBOA-induced increases in extracellular glutamate, AIDA did not. In contrast, all three group I antagonists reversed the increase in extracellular glutamate elicited by stimulating mGluR1/5. In vitro evaluation revealed that similar to CPG, LY 367385 inhibited xc-, and that stimulating or inhibiting mGluR1/5 did not directly affect [3H]-glutamate uptake via xc- or X-AG. These experiments reveal that although inhibiting xc- cannot reduce basal extracellular glutamate in the prefrontal cortex, the accumulation of extracellular glutamate following blockade of X-AG arises predominately from xc-. The accumulation of glutamate elicited by mGluR1/5 stimulation does not appear to result from modulating X-AG, xc- or synaptic glutamate release.
Key words:
glutamate exchange, glutamate pools, glutamate uptake, medial prefrontal cortex, microdialysis, non vesicular glutamate release
This article has been cited by other articles:
![]() |
K. N. Hascup, E. R. Hascup, F. Pomerleau, P. Huettl, and G. A. Gerhardt Second-by-Second Measures of L-Glutamate in the Prefrontal Cortex and Striatum of Freely Moving Mice J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 725 - 731. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Madayag, D. Lobner, K. S. Kau, J. R. Mantsch, O. Abdulhameed, M. Hearing, M. D. Grier, and D. A. Baker Repeated N-Acetylcysteine Administration Alters Plasticity-Dependent Effects of Cocaine J. Neurosci., December 19, 2007; 27(51): 13968 - 13976. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Durstewitz and T. Gabriel Dynamical Basis of Irregular Spiking in NMDA-Driven Prefrontal Cortex Neurons Cereb Cortex, April 1, 2007; 17(4): 894 - 908. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Namkoong, S.-S. Shin, H. J. Lee, Y. E. Marin, B. A. Wall, J. S. Goydos, and S. Chen Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma Cancer Res., March 1, 2007; 67(5): 2298 - 2305. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Shih, H. Erb, X. Sun, S. Toda, P. W. Kalivas, and T. H. Murphy Cystine/Glutamate Exchange Modulates Glutathione Supply for Neuroprotection from Oxidative Stress and Cell Proliferation J. Neurosci., October 11, 2006; 26(41): 10514 - 10523. [Abstract] [Full Text] [PDF] |
||||